drugset / Trial / NCT07169175
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NaSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2025-12-01
- Primary completion
- 2028-03-30
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNUG01 | Gene therapy (AAV / viral vector) | — | Intrathecal |